Date post: | 16-Jul-2015 |
Category: |
Health & Medicine |
Upload: | critical-outcome-technologies-inc |
View: | 40,735 times |
Download: | 0 times |
22
Critical Outcome Technologies Inc.
Rapidly developing targeted therapies to better meet the needs of patients
TSX-V: COT
OTCQB: COTQF
3
Highlights
1
2
3
COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015
CHEMSAS – proprietary drug discovery engine using machine-based learning
Strong pipeline of opportunities in oncology and other therapeutic areas
4
COTI-2: a promising advance
Potential breakthrough treatment for many cancers
Effective against many common cancers with a p53 gene mutation
> 50% of all human cancers have a p53 mutation (eg. ~ 95% of serous ovarian cancers)
5
COTI-2 background
N
NNH
S
N
N
N
3rd generation Thiosemicarbazone
A small molecule discovered by our CHEMSAS process
Engineered for low toxicity and easily synthesized in 3 steps
Demonstrates strong in vitro and in vivo activity
5
6
COTI-2: first- and best-in-class potential
Novel p53-dependent mechanism of action
Orally bio-available and effective at low dose
Low toxicity in preclinical development
Opportunity for single agent and combination therapy
Strong IP protection in place
7
COTI-2 and tumor volumes
Tumors significantly reduced by COTI-2 in all treatment groups relative to vehicle control
8
COTI-2 reduces p53 resistant protein levels
COTI-2 significantly reduces p53 mutant protein levels and significantly increases wild-type p53 protein levels in TOV-112D cells likely by inducing a conformational change
•(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)
Mutant p53 Levels in the presence/absence of COTI-2
0
20
40
60
80
100
TOV-112D H460
Me
an F
luo
resc
en
ce In
ten
sity
(A
rbit
rary
Un
its)
Cell Line
Control
COTI-2
*
9
COTI-2: effects on p53 protein levels
COTI-2 has no significant effect on p53 protein levels in the H460 cell line, which do not carry the mutant p53 protein
•(*) Significant difference in p53 protein levels between COTI-2 treated and untreated cells (control)
Wild-type p53 Levels in the Presence/Absence of COTI-2
0
20
40
60
80
100
120
TOV-112D H460
Me
an F
luo
resc
en
ce In
ten
sity
(A
rbit
rary
Un
its)
Cell Line
Control
COTI-2
*
10
MD Anderson relationship
10
Confirmed COTI-2’s novel p53 dependent MOA
Confirmed selective & potent anti-cancer activity
Identified effective dosage 60% lower than in prior animal experiments
11
COTI-2: the pathway to the clinic
Granted orphan drug status for ovarian cancer by FDA in June 2014
Completed final pre-clinical studies
Signed LOI with MD Anderson for Phase 1 clinical development
Grant of Investigational New Drug status in May 2015
Commence Phase 1 clinical trial in 3rd quarter of calendar 2015
12
COTI-2: next steps
12
Complete Phase 1: 46 patients in gynecologic cancers
Expand indications and combination therapies
Phase 2: add value – create partnerships
1313
Proprietary, machine learning (AI) based drug discovery platform technology
Big Data analysis solutions
Building a robust pipeline with CHEMSAS®
14
Costly failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’
Increased probability of clinical & commercial success
Database driven computational replication of traditional ‘wet lab’ drug discovery process
14
Advantages of CHEMSAS®
15
Drugs in our pipeline
TherapyLibrary /Compound
Target CHEMSAS Lead Selection
Synthesis Preclinical Phase 1
Oncology
COTI-2
AML
Colon
Small Cell Lung Cancer Library
COTI-219
COTI-4
COTI-58
6 other leads
Plus projects for MRSA, Multiple sclerosis, Alzheimer’s, and HIV Integrase Inhibitors
16
Summary
1
2
3
COTI-2 – lead program in oncology entering Phase 1 clinical trial in 2015
CHEMSAS – proprietary drug discovery engine using machine-based learning
Strong pipeline of opportunities in oncology and other therapeutic areas
17
When used anywhere in this presentation, whether oral or written, the words expects, believes,anticipates, estimates and similar expressions are intended to identify forward-lookingstatements. Forward-looking statements may include statements addressing future financial andoperating results of Critical Outcome Technologies Inc. (COTI).
COTI bases these forward-looking statements on its current expectations about future events.Such statements are subject to risks and uncertainties including, but not limited to, thesuccessful implementation of COTI’s strategic plans, the acceptance of new products, theobsolescence of existing products, the resolution of potential patent issues, competition,changes in economic conditions, and other risks described in COTI’s public documents such aspress releases and filings with the Toronto Stock Exchange and the Ontario SecuritiesCommission.
All forward-looking statements are qualified in their entirety by the cautionary statementsincluded in this document and such filings. These risks and uncertainties could cause actualresults to differ materially from results expressed or implied by forward-looking statementscontained in this presentation. These forward-looking statements speak only as of the date ofthis presentation.
Disclaimer
Follow CriticalOutcome on Twitter,
Facebook, YouTube and SlideShare